Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA RPL39
- Development stage
- Preclinical
- Lead developer
- Houston Methodist
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
siRNA RPL39 is an investigational small interfering RNA (siRNA) therapeutic designed to target and silence the expression of the RPL39 gene, which encodes Ribosomal Protein L39 (a component of the 60S ribosomal subunit). Developed primarily by researchers at Houston Methodist and Weill Cornell Medicine, siRNA RPL39 is being evaluated in preclinical studies for the treatment of triple-negative breast cancer (TNBC), metaplastic breast cancer (MpBC), and pancreatic cancer. By silencing RPL39, the drug suppresses tumor cell proliferation, induces apoptosis, and reduces metastasis, particularly by inhibiting nitric oxide synthase (NOS) signaling and reducing breast cancer stem cell self-renewal. Various nanoparticle-based delivery systems, including multistage vector (MSV) liposomal nanoparticles and biomimetic leukosomes, have been utilized to facilitate its in vivo delivery.
- Other names
- RPL39 siRNARPL-39 siRNARPL 39 siRNAsiRNA RPL39siRPL39siRPL-39siRPL 39
02
Targets
Ribosomal protein L39 messenger RNANOS2 (Nitric Oxide Synthase 2)
Beyond the preview
Go deeper on siRNA RPL39.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA RPL39.